Caribou Biosciences

📍 Berkeley, United States🗓 Founded 2011👥 152 employees💰 Last funded Jul 2019
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met. Interested in joining our team? Please check out our jobs at https://cariboubio.bamboohr.com/jobs/
3
Total investors
0
Early stage
2
Mid stage
1
Late stage
2011
Founded
Investor geography1 country
United States
3
Investor activity2015–2019 · investors recorded per year
201512016120191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Caribou Biosciences?
Caribou Biosciences has 3 investors on record on gritt.io, 2 mid-stage and 1 late-stage investors.
When did Caribou Biosciences last raise funding?
The most recent investment in Caribou Biosciences recorded on gritt.io was in July 2019.
When was Caribou Biosciences founded?
Caribou Biosciences was founded in 2011.
What industry is Caribou Biosciences in?
Caribou Biosciences operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Caribou Biosciences based?
Caribou Biosciences is headquartered in Berkeley, United States.